Effectiveness of Convalescent Immune Plasma Therapy
Not Applicable
Completed
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Other: Convalescent Immune Plasma
- Registration Number
- NCT04442958
- Lead Sponsor
- Bagcilar Training and Research Hospital
- Brief Summary
The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
- Detailed Description
The aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe Covid-19 patients followed up in critical care unit.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Convalescent Plasma Therapy Group Convalescent Immune Plasma One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
- Primary Outcome Measures
Name Time Method Plasma fibrinogen level 7. day Coagulopathy
Plasma procalcitonin level 7. day Infection markers
Plasma ferritin level 7. day Acute phase reactant
D-Dimer level 7. day Hypercoagulability
C-Reactive protein level 7. day Infection markers
Lymphocyte count 7. day Infection markers
- Secondary Outcome Measures
Name Time Method Arterial Oxygen level 7. day Arterial oxygenation
Fractional Inspired Oxygen Level 7. day Arterial oxygenation
Partial Oxygen Saturation level 7. day Arterial oxygenation
Trial Locations
- Locations (1)
Istanbul Bagcılar Training and Research Hospital
🇹🇷Istanbul, Turkey